What Heidi Overton Said About Vapes at Her FDA Confirmation Hearing
Posted by Alli Boughner on Sep 28th 2026
September 24, 2026
Flavored vapes came up repeatedly during Dr. Heidi Overton’s Senate confirmation hearing today. Senators pressed the FDA commissioner nominee on youth use, recent authorizations, political influence, the PMTA backlog and enforcement. Her answers offered some encouragement for adults who rely on flavored alternatives to cigarettes. They also left a big question unanswered: will independent manufacturers actually get a timely, fair review?
Here are the vape exchanges and what I took from them. This account uses the hearing excerpts available at publication and contemporaneous reporting; the committee has posted video but has not posted a searchable transcript. I have paraphrased where I cannot verify exact wording.
Collins challenged the flavored authorizations
Sen. Susan Collins (R-Maine) said she feared FDA’s recent authorizations of flavored nicotine pouches and vapes would reverse progress against youth nicotine use. She cited the fact that nearly 90% of young people who currently vape use flavored products and pressed Overton to say whether she supported the decisions.
Overton did not disavow the authorizations. She emphasized protecting children, then said career FDA reviewers recommended the products because they met the statutory “appropriate for the protection of the public health” standard and because many adults who smoke prefer flavors. If lawmakers believe that standard is wrong, she suggested, they should change the statute.
That matters. Collins was inviting her to treat the presence of a flavor as reason enough to reject a product. Overton answered by pointing to the actual legal test and the adult side of the equation.
One correction is essential: the nearly 90% figure describes the proportion of youth e-cigarette users who use flavored products. It does not mean nearly 90% of people who use flavored vapes are teenagers. Youth protection belongs in the analysis, but so do adults who switched from smoking.
The timing was also blurred in Collins’s remarks. FDA announced its Glas vape authorizations on May 5, while other pouch decisions came later. Pouches and vapes are different product categories, and lumping their authorizations together obscures what FDA actually evaluated.
Collins asked about the review backlog
Collins then asked how Overton would make the Center for Tobacco Products more efficient, predictable and transparent for manufacturers.
Overton said a stronger legal market matters for adults using these products to move away from cigarettes. She paired that with youth safeguards, enforcement against illicit vapes, coordination with the Justice Department and Homeland Security, and work to fix the backlog. She referred to 48 authorized e-cigarette products.
I agree with the goal. But she did not give manufacturers a timeline, measurable review target or explanation of how a small independent applicant gets through the process. If FDA wants a functioning legal market, it has to review applications and issue defensible decisions. Enforcement cannot create more authorized choices by itself.
Overton also described access for people using vapes for “smoking cessation.” That is a statement about how adults use the products; a tobacco marketing authorization is not an FDA approval of a medicine to treat smoking.
Collins returned to youth flavors
Collins pressed Overton again, asking whether she knew flavored vapes were popular with teenagers. Overton agreed that protecting children is a core priority. She did not retract her earlier acknowledgment that adult smokers use and prefer flavored products.
There is no contradiction in recognizing both. The question for FDA is how it assesses adult benefit, youth risk and safeguards for each application under the law Congress wrote. A hearing sound bite about flavors cannot substitute for that review.
Murphy questioned political influence
Sen. Chris Murphy (D-Connecticut) raised Reynolds’s reported political donation and a subsequent White House meeting and calls, asking whether the sequence connected to FDA’s Glas vape authorizations.
Overton rejected his framing. She said the president recognizes that adults use vapes to quit smoking, promised to follow the statutory public health standard if confirmed, and again pointed to the recommendation from FDA career staff.
The allegation of political interference should be taken seriously and tested against evidence. But the chronology Murphy offered does not by itself prove that a donation caused an authorization. Equally, saying career staff supported an authorization does not fully answer whether political pressure affected the timing or final decision. Those are separate questions.
It is also worth keeping the companies straight: the flavored vape authorization at issue was for Glas, not Reynolds. That distinction matters, especially when discussing who benefited from any decision.
Moody pressed her on illicit imports
Sen. Ashley Moody (R-Florida) raised illicit Chinese-made vapes. Overton committed to cracking down on those products, according to contemporaneous hearing coverage. Her response fits with the enforcement approach she described to Collins, including work with other federal agencies.
Unauthorized imports are a legitimate enforcement concern. But manufacturers that submitted applications deserve actual decisions, and adults deserve access to products that can meet the statutory standard. FDA needs to do both parts of its job.
What we learned—and what we still need to see
Overton did something significant under direct pressure: she defended the possibility of flavored-product authorizations under the existing law and acknowledged adult flavor preferences. She did not promise to reverse the Glas decision simply because its flavors make for uncomfortable questions at a Senate hearing.
Still, I’ve heard promises about a predictable review process before. Today brought no specific plan for the backlog, no commitment to consistent treatment of independent applicants and no answer to why so few manufacturers have made it across FDA’s finish line.
Protect kids. Enforce the law. Then apply that same law fairly to the adults trying to leave cigarettes behind and to every company willing to put its product through review. Overton’s answers leave room for that approach. What matters now is whether she would actually deliver it.